Lumos Pharma Inc

Lumos Pharma — Q1 2023 Earnings Presentation

8 slides from Lumos Pharma's earnings presentation, May 3, 2023

  1. Slide 1: First Quarter 2023 Financial Results & Clinical Update

    1 First Quarter 2023 Financial Results & Clinical Update May 3, 2023

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation contains proprietary and confidential information of Lumos Pharma, Inc. (“Lumos,” “we,” “us” and “our”), and such content should be considered “Confidential Information” and covered by your confidentiality obligations to Lumos. This presentation is made

  3. Slide 3: Agenda

    3 Agenda • Lisa Miller, Senior Director of Investor Relations • Rick Hawkins, Chief Executive Officer & Chairman • Rick Hawkins, Chief Executive Officer & Chairman • John McKew, PhD, President & Chief Scientific Officer • David B. Karpf, MD, Chief Medical Officer • Lori Lawley, Chief Financial Offic

  4. Slide 4: OraGrowtH210 Trial Baseline Characteristics at 50% & 100% Enrollment

    4 OraGrowtH210 Trial Baseline Characteristics at 50% & 100% Enrollment LUM-201 1.6 mg Mean (SD) N=10 rhGH Mean (SD) N=10 LUM-201 1.6 mg Mean (SD) N=22 rhGH Mean (SD) N=20 Age (months) 99.3 (28.3) 90.3 (26.7) 95.2 (27.3) 91.4 (23.3) Height (cm) 114.6 (9.6) 111.6 (11.9) 113.0 (11.0) 112.3 (10.5) Heigh

  5. Slide 5: Additional Highlights: International Meeting of Pediatric Endocrinologists (IMPE)

    5 Additional Highlights: International Meeting of Pediatric Endocrinologists (IMPE) Oral Presentation: • Dose-dependent Increase in GH AUC0-12h with LUM-201 in Idiopathic Pediatric GH Deficiency (iPGHD) from the Interim Analysis Data of the OraGrowtH212 Trial, Cassorla, F. Poster Presentation: • Bas

  6. Slide 6: Additional Highlights

    6 Additional Highlights • Oral Presentation: Growth Response to LUM-201 in the OraGrowtH210 Trial in Idiopathic Pediatric Growth Hormone Deficiency (iPGHD): Interim Analysis Data (41 Subjects), Dauber, A. • Poster Presentation: Observed IGF-1 Serum Concentration Increase Within Normal Range After Pr

  7. Slide 7: Lumos Pharma Financial Information as of March 31, 2023

    7 Lumos Pharma Financial Information as of March 31, 2023 Values in USD Cash, equivalents & short-term investments $58.0M Debt $0 Shares Outstanding 8.2M Cash Use per Quarter in 2023 $9.5-$10.5M Fiscal Year End December 31 LUMO Cash, cash equivalents, and short-term investments to support operations

  8. Slide 8: Investment Highlights

    8 Investment Highlights Lead asset targeting children with growth disorders PGHD = Pediatric Growth Hormone Deficiency * USA, Germany, France, Italy, Spain, UK, Japan (Grandview Research, Growth Hormone Market Forecast, 2019) Novel Oral Rare Disease Asset Pipeline in a Product Solid Financial Positi

Lumos Pharma — Q1 2023 Earnings Presentation on 6ix